Dr. Lal Path Labs Director Vasuta Agarwal appointed
Dr. Lal Path Labs (LALPATHLAB) said Vasuta Agarwal, Director, has been appointed; and Lal Path Labs Ltd., Independent Director, has been appointed; and Vasuta Agarwal as Additional has been appointed. The company is valued at about ₹32,282 crore.
What happened
Dr. Lal Path Labs (LALPATHLAB) told the exchanges on 4 November 2026 at 01:47 PM that Vasuta Agarwal, Director, has been appointed; and Lal Path Labs Ltd., Independent Director, has been appointed; and Vasuta Agarwal as Additional has been appointed.
From the filing: "Lal Path Labs Ltd. has informed the Exchange regarding Appointment of Ms Vasuta Agarwal as Additional Director designated as Non- Executive Independent Director of the company w.e.f."
Company snapshot
Dr. Lal Path Labs is a mid-cap company in the Healthcare sector, with a market value of about ₹32,282 crore.
The stock last traded at ₹1,925.7, against a 52-week range of ₹1,272.6–₹2,038.6 (5.5% below the high).
Before this filing the shares had moved −5.0% over the month and −0.7% over three months. Average daily turnover over the last 20 sessions was about ₹44.85 crore.
Promoters held 53.19% at the end of Q1 FY27, down 0.02% points from the previous quarter. Foreign institutions owned 17.36% and domestic institutions 21.59%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 670 | 132.4 | 15.88 |
| Q2 FY26 | 731 | 150.6 | 18.05 |
| Q3 FY26 | 660 | 90.5 | 5.42 |
| Q4 FY26 | 703 | 131.3 | 7.86 |
| Q1 FY27 | 798 | 169.5 | 10.15 |
What history shows
BCEIE's records show 2 previous management change filings from the company since May 2026.
Across 119 similar disclosures by other Healthcare companies, shares moved +0.9% on average the next day and +1.7% over five days; 48% of them rose the next day.
Market-wide, 4,237 management change filings with an impact score of 50 or more saw an average next-day move of −0.1%, with 44% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- The appointment of a successor and any change in strategy or guidance.
- 4 November 2026: Board meeting — Financial Results/Other business matters.
- 4 November 2026: Board meeting — Dividend.
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.